<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AC8840F7-3488-4B1E-B9F4-8446A50C8DFB"><gtr:id>AC8840F7-3488-4B1E-B9F4-8446A50C8DFB</gtr:id><gtr:name>Oxford Biotherapeutics Ltd</gtr:name><gtr:address><gtr:line1>94A INNOVATION DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RZ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC8840F7-3488-4B1E-B9F4-8446A50C8DFB" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>AC8840F7-3488-4B1E-B9F4-8446A50C8DFB</gtr:id><gtr:name>Oxford Biotherapeutics Ltd</gtr:name><gtr:address><gtr:line1>94A INNOVATION DRIVE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RZ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>783635.0</gtr:offerGrant><gtr:projectCost>1567270.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60A4AFD1-7658-44F7-9283-04A1C114F16F" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>60A4AFD1-7658-44F7-9283-04A1C114F16F</gtr:id><gtr:name>Summit Therapeutics Plc</gtr:name><gtr:address><gtr:line1>85b Park Drive</gtr:line1><gtr:city>Abingdon</gtr:city><gtr:postCode>OX14 4RY</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>185074.0</gtr:offerGrant><gtr:projectCost>370148.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=100043"><gtr:id>B8A981C2-AFC1-4B5C-B8F1-A9598C4F2ABA</gtr:id><gtr:title>Drug safety protein biomarker.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>100043</gtr:grantReference><gtr:abstractText>To establish a hepatotoxicity biomarker database in zebrafish embryos (ZFEs) using compounds with known toxicities. To use this database in parallel with OGeS''s existing OGAP database to select and validate potential drug safety protein biomarkers in both ZFEs and rodents (and ultimately, man). To develop highthroughput Ordered Peptide Array (OPA) screens initially, followed by antibody (Ab) based platform technologies. Biomarkers will be selected on the basis of quantitative changes correlating to characteristic morphologic and/or phenotypic observations in ZFE. Commercialised OPA and/or Ab screens (applicable to zebrafish, rat and human samples) will be offered to pharma industry in parallel to phenotypic zebrafish screens to improve drug discovery efficiency in preclinical safety asessment initially, with potential clinical applications explored subsequently. and hepatotoxicity.</gtr:abstractText><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>968709</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">100043</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>